Abstract 5957
Background
EML4-ALK fusion is one of the major activating kinase mutations in NSCLC. It occurs with varying frequency in different populations and is known to associate with clinical features such as smoking history and age. Based on different breakpoints in EML4 and ALK genes, there exist several fusion subtypes (variants), which have been reported to respond differently to ALK inhibitors. In this study, we investigated the landscape of EML4-ALK in Chinese NSCLC patients and correlated fusion variants with clinical factors.
Methods
FFPE tumor and matched blood samples of over 1000 Chinese NSCLC patients were collected for NGS-based 450 cancer genes panel assay. Genomic alterations including single nucleotide variations (SNV), short and long insertions/deletions (Indel), copy number variations (CNV) and gene rearrangements in selected genes were assessed.
Results
A total of 73 EML4-ALK fusion samples were identified. In our cohort, younger patients were more likely to harbor ALK fusions, consistent with previous reports. In terms of EML4-ALK fusion variants, we observed three major subtypes: 30 E6:E20 (variant 3) cases, 20 E13:E20 (variant 1), and 11 E20:E20 (variant 2). Interestingly, E6-E20 was enriched in male patients (18 vs 12), while E13-E20 was enriched in female patients (13 vs 7); furthermore, for the E13-E20 variant all 13 female patients were younger than 60, while 4 out of 7 male patients were older than 60 (p = 0.007). To complete the picture, other subtypes of EML4-ALK fusion in our cohort included: 4 E18:E20, 4 E14:E20, 3 E2:E20, and 1 E21:E20.
Conclusions
EML4-ALK fusion is known to associate with clinical features including race, age, and smoking history. Our profiling of EML4-ALK alteration in Chinese NSCLC patients not only revealed the composition of fusion subtypes, but also connected variants with demographic factors such as gender and age. Our initial results need to be validated in larger cohorts and/or different populations. Given that different fusion variants respond differently to ALK inhibitors, our findings could have important implications.
Clinical trial identification
Legal entity responsible for the study
OrigiMed.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A. Wang, H. Chen, Y-A. Dong: Employee: OrigiMed. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract